Company / Financials
ENANTA PHARMACEUTICALS INC Financials
FY2013-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$79.2M
FY2025 · -8.1% YoY
Net Income
-$133.8M
FY2025 · -9.9% YoY
Profit Margin
-168.9%
FY2025 · net income / revenue
ROE
-103.9%
FY2025 · return on equity
Total Assets
$280.7M
FY2025
Total Debt
-
FY2025
Equity
$128.8M
FY2025
ROA
-47.7%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$79.2M-8.1% YoYNet Income HistoryProfit after all expenses and taxes-$133.8M-9.9% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$137.2M-10.8% YoYSG&A Expense HistorySelling, general, and administrative expenses$52.9M+16.3% YoYR&D Expense HistoryResearch and development spending$163.5M-0.6% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$2.8M+751.5% YoYEPS (Basic) HistoryBasic earnings per share-$6.38-8.0% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$6.38-8.0% YoYShares Outstanding HistoryWeighted average diluted shares outstanding21.2M+0.6% YoY